| scholarly article | Q13442814 |
| P50 | author | Ton Lisman | Q44101470 |
| P2093 | author name string | Jelle Adelmeijer | |
| H Karel Nieuwenhuis | |||
| Philip G De Groot | |||
| Sultana Moschatsis | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 1864-1870 | |
| P577 | publication date | 2002-10-31 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation | |
| P478 | volume | 101 |
| Q24299888 | A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides |
| Q44537661 | Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism |
| Q86299650 | An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome |
| Q37608557 | Blood flow devices in medical research and clinical testing in humans: are we approaching personalized medicine? |
| Q36536184 | Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. |
| Q33358457 | Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients |
| Q79788208 | Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity |
| Q45869189 | Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. |
| Q39322760 | Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders |
| Q21203054 | Glanzmann thrombasthenia |
| Q45867804 | GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa |
| Q47361171 | Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. |
| Q38859457 | Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. |
| Q90384225 | Inherited platelet functional disorders: General principles and practical aspects of management |
| Q73690484 | Mechanism of action of recombinant factor VIIa |
| Q37240186 | Modeling the action of factor VIIa in dilutional coagulopathy |
| Q26766249 | New Insights Into the Treatment of Glanzmann Thrombasthenia |
| Q45956023 | Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding. |
| Q45855157 | Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. |
| Q37853216 | Proteases as therapeutics |
| Q37558713 | Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation |
| Q33367864 | Qualitative disorders of platelets and megakaryocytes |
| Q35839531 | Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding |
| Q36313315 | Recombinant activated factor VII and the anaesthetist. |
| Q45869349 | Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition |
| Q44763681 | Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors |
| Q48399276 | Surgical treatment of cecal cancer in a patient with Glanzmann's thrombasthenia: report of a case |
| Q38020983 | Treatment of inherited platelet disorders |
| Q38059249 | Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment |
| Q33382014 | Understanding the therapeutic action of recombinant factor VIIa in platelet disorders |
| Q38221820 | Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature |
Search more.